checkAd
    Arcturus Therapeutics Holdings Aktie
    27,26
     
    USD
    +1,75 %
    +0,47 USD
    Letzter Kurs 02:00:00 Nasdaq
    27,21
     
    USD
    1.700 STK
    Geldkurs 10.05.24
    27,26
     
    USD
    200 STK
    Briefkurs 10.05.24
    ISIN: US03969T1097 · WKN: A2PMAS · SYM: ARCT · USA

    Neueste Nachrichten

    Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
    08.05.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
    25.04.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
    07.03.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
    26.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
    22.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
    20.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
    05.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
    21.12.23 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    04.12.23 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
    28.11.23 · Business Wire (engl.) · CSL
    Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
    27.11.23 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
    14.11.23 · Business Wire (engl.) · Arcturus Therapeutics Holdings